[Featured Stock] JLK Enters Upper Limit Price Amid Expectations for AI Medical Industry

[Image source=Yonhap News]

[Asia Economy Reporter Hwang Junho] The stock price of JLKE, a domestic medical company, is showing strong performance in the early trading session on the 16th.

As of 9:25 AM on the 16th, JLKE recorded 7,940 KRW, up 29.95% from the previous close. This is analyzed as a result of growing expectations for the artificial intelligence medical industry.

Korea Investment & Securities evaluated JLKE on the same day, stating that high growth is expected in the medical artificial intelligence (AI) industry. However, they did not provide an investment opinion or target price. JLKE is a medical AI company that analyzes medical images such as CT (computed tomography) and X-rays using AI, and provides data analysis solutions utilizing AI.

Jung Songhoon, a researcher at Korea Investment & Securities, said, "Currently, medical artificial intelligence is in the early stages of technology, so it is still limited to assisting diagnosis in some large hospitals. However, as technology advances, the speed and accuracy of medical AI diagnosis will improve, and along with institutional improvements such as insurance coverage and amendments to medical laws, explosive growth in the medical AI industry will be possible."

Meanwhile, a media outlet reported on the same day that JLKE received emergency approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), under the Ministry of Health, Labour and Welfare, for its AI lung disease solution 'JVIEWER-X'.

This content was produced with the assistance of AI translation services.